×
App Icon
The Standard e-Paper
Kenya’s Boldest Voice
★★★★ - on Play Store
Download App

Disappointment as heart drug darapladib fails in second late-stage trial

LONDON: GlaxoSmithKline said its drug darapladib had not reduced heart attacks or other major events in patients with acute coronary syndrome, marking another disappointment for the innovative heart medicine.

Darapladib had already failed in a late-stage trial for patients with well-treated heart disease.

Get Full Access for Ksh299/Week.
Bold Reporting Takes Time, Courage and Investment. Stand With Us.
  • Unlimited access to all premium content
  • Uninterrupted ad-free browsing experience
  • Mobile-optimized reading experience
  • Weekly Newsletters
  • MPesa, Airtel Money and Cards accepted
Already a subscriber? Log in